AML & MDS: Older Patients
Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients
(Medscape requires a one-time free registration to access the activity)
Explore practical applications of classification and research data to compare treatment choices for older AML and MDS patients, including:
- How diagnostic testing has changed the timing of therapeutic choices and if age should be considered
- Applying data to mitigate risk and optimize the benefit among new drugs, transplantation, and combination approaches
- What coverage options are available for Medicare-eligible patients
This activity is intended for hematologists, oncologists, and other healthcare professionals who treat patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
- Identify disease- and patient-related factors that predict outcomes of hematopoietic cell transplantation (HCT), new drugs, or combination therapy in older patients with MDS and AML
- Explain recent clinical trial results that have influenced the selection of patients in trials for treatment of MDS and AML.
- Compare the risks and benefits of treatment options and how timing of therapy choices affects outcomes
- Describe appropriate candidates for a prospective study on outcomes of HCT in adults 65 years of age and older with MDS
- Frederick R. Appelbaum, M.D.
Executive Director, Seattle Cancer Care Alliance; Director, Fred Hutchinson Cancer Research Center; Professor, University of Washington School of Medicine, Seattle, Washington
- Stephen J. Forman, M.D.
Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation; Clinical Director, Cancer Immunotherapeutics & Tumor Immunology, City of Hope, Duarte, California
- Gail J. Roboz, M.D.
Director, Leukemia Program; Associate Professor of Medicine, Weill Medical College, Cornell University, New York, New York.
- David Steensma, M.D.
Associate Professor of Medicine, Harvard Medical School; Adult Leukemia Program, Dana-Farber Cancer Institute; Hematological Oncology Service, Brigham & Women’s Hospital, Boston, Massachusetts
- Willis Navarro, M.D.
Vice President, Transplant Medical Services, National Marrow Donor Program®/Be The Match®, Minneapolis, Minnesota
If you have any questions regarding this activity or for assistance for people with disabilities, grievances, please email email@example.com.